Geode Capital Management LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,122,889 shares of the medical research company's stock after purchasing an additional 103,851 shares during the period. Geode Capital Management LLC owned about 2.26% of Amgen worth $3,893,771,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at about $25,000. Strategic Financial Concepts LLC acquired a new stake in Amgen in the 2nd quarter worth about $26,000. Legacy Investment Solutions LLC purchased a new stake in Amgen during the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen during the second quarter valued at approximately $30,000. Finally, nVerses Capital LLC purchased a new position in shares of Amgen in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.50% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on AMGN. Barclays raised their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. Leerink Partners reduced their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Dbs Bank upgraded Amgen to a "strong-buy" rating in a report on Monday, September 16th. Wolfe Research started coverage on Amgen in a research note on Friday, November 15th. They issued a "peer perform" rating for the company. Finally, Royal Bank of Canada lowered their price target on shares of Amgen from $360.00 to $330.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $319.68.
View Our Latest Stock Report on Amgen
Amgen Stock Down 0.7 %
AMGN stock traded down $1.88 during trading on Tuesday, hitting $275.75. 2,755,082 shares of the company's stock were exchanged, compared to its average volume of 2,606,921. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52-week low of $257.80 and a 52-week high of $346.85. The business has a 50-day moving average price of $305.69 and a two-hundred day moving average price of $315.66. The stock has a market capitalization of $148.22 billion, a price-to-earnings ratio of 35.31, a PEG ratio of 3.02 and a beta of 0.55.
Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the prior year, the firm posted $4.96 earnings per share. Amgen's revenue for the quarter was up 23.2% on a year-over-year basis. As a group, equities research analysts expect that Amgen Inc. will post 19.51 EPS for the current year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 9th. Shareholders of record on Monday, November 18th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.26%. The ex-dividend date was Monday, November 18th. Amgen's dividend payout ratio is presently 115.24%.
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
